Q-omics provides the consensus-scored LCE1E profile across patient tissues and cancer cell-line models. LCE1E expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LCE1E is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, LCE1E RNA expression shows 6,873 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where LCE1E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCE1E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCE1E survival associations across molecular data types. LCE1E RNA expression shows survival associations in the most cancer types (15), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCE1E RNA expression–survival associations across cancer types. High LCE1E expression shows unfavorable associations in KIRP, THYM, PAAD and SKCM, but favorable associations in HNSC and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LCE1E RNA expression.
This table summarizes LCE1E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LCE1E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCE1E shows lower tumor expression in BLCA and higher tumor expression in COAD, LUSC, THCA, HNSC and LIHC. The COAD box plot shows higher LCE1E RNA expression in tumor versus normal tissue (log2 FC = +0.092, t-test p = .002).
This table shows molecular features associated with LCE1E in patient tissues and cancer cell lines. In patient samples, LCE1E shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LCE1E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
